The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isIn phase 2.
- What to watchSevere belly pain that spreads to the back while using Pemvidutide.
How Pemvidutide works
GLP-1/glucagon dual agonist — glucagon arm drives energy expenditure and hepatic fat loss on top of GLP-1 appetite control.
The first thing to fix is which drug this is. Pemvidutide is sold on this site as a weight-loss compound, and the entire peer-reviewed record for it is liver: three randomized trials, all in fatty liver disease, two of them with a biopsy or an MRI endpoint Harrison 2024 Browne 2025 Noureddin 2025.
The mechanism: GLP-1 plus glucagon, and the glucagon arm is the whole point. A GLP-1 receptor agonist reduces intake. A glucagon receptor agonist increases expenditure and, specifically, drives hepatic fat oxidation — the liver burns its own stored triglyceride.
- Injectable
On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)
Where to get Pemvidutide
When a vetted partner does, the link and code go here.
Research on Pemvidutide5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
In phase 2. Altimmune's GLP-1/glucagon dual agonist. The MOMENTUM obesity trial reported around 15.6% weight loss at 48 weeks, with the company highlighting that roughly 75% of the loss was fat mass rather than lean — unusually high preservation for this class.
Phase 2 in MASH reported significant liver fat reduction. Lean-mass preservation is a claim to watch rather than accept — body-composition sub-studies are small and methodologically variable.
Correlative data
No marketed use. Trial tolerability is class-typical, with the glucagon-driven heart rate increase noted as with the other duals.
How the mechanism reads
A GLP-1/glucagon dual agonist engineered with a 1:1 receptor ratio — a deliberately higher glucagon weighting than most competitors, using a lipid modification for duration.
MechanisticThe ratio is the whole design thesis. More glucagon means more energy expenditure and more hepatic fat oxidation, which is the mechanistic case for both the lean-mass and liver findings. It also means more of glucagon's downsides, and where the optimal ratio sits is genuinely unsettled.
Mechanistic
Sources
- Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology 2024 · PMID 39002641
- Browne SK, et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Reports 2025 · PMID 41113119
- Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025 · PMID 41237796
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine 2024 · PMID 38858523
- Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
- Li F, et al. Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes, Obesity and Metabolism 2026 · PMID 42310888
- Yang Y, et al. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. Diabetes, Obesity and Metabolism 2023 · PMID 37860884
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
- Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
- Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
Pemvidutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid cancer or MEN2 in the family: the GLP-1 arm of pemvidutide shares the rodent C-cell signal.
- Decompensated cirrhosis: the glucagon arm acts on the liver, and a failing liver is untested.
- Pancreatitis history, or type 1 diabetes and insulin use.
- Pregnancy or conception plans: glucagon-receptor activity in a fetal liver has no human data.
What’s expected
- Falling appetite and weight from the GLP-1 arm.
- Marked drop in liver fat and liver enzymes, from balanced glucagon receptor activity.
- Nausea and loose stools early.
- A small rise in resting pulse.
Watch for
- Severe belly pain that spreads to the back while using Pemvidutide.
- Yellow eyes, dark urine or pale stools.
- Heart pounding at rest while using Pemvidutide.
- Vomiting that will not settle.
Labs that tell you it’s working
- Comprehensive Metabolic Panel (CMP)
- Lipase
- Lipid Panel
- Enhanced Liver Fibrosis (ELF) Test
Balanced GLP-1 and glucagon agonist built for fatty liver; liver enzymes show it working, lipase shows pancreas stress. PMID 39002641 PMID 41237796
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Pemvidutide FAQ4 common questions
- Is Pemvidutide approved for human use?
- No. Pemvidutide is a research compound.
- What is Pemvidutide researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Lipase; Lipid Panel; Enhanced Liver Fibrosis: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Pemvidutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



